Bank of America Securities Keeps Hold Rating on Arcus Biosciences with $12 Price Target

Bank of America Securities analyst Jason Zemansky reiterated a Hold rating on Arcus Biosciences with a $12.00 price target. Arcus Biosciences has a Strong Buy analyst consensus rating with a $28.86 average price target, representing a 174.07% upside. The company has a market cap of $1.12B and a P/E ratio of -3.32.

Arcus Biosciences (NYSE: RCUS), a clinical-stage biopharmaceutical company, has announced its participation in three upcoming investor conferences in September 2025. The company will be represented by its management team at the following events:

1. Citi’s 2025 Biotech Back to School Conference
- Date: Wednesday, September 3rd, 2025
- Location: Boston, MA
- Format: Fireside chat & 1x1 meetings
- Time: 11:15 a.m. ET

2. H.C. Wainwright 27th Annual Global Investment Conference
- Date: Tuesday, September 9th, 2025
- Location: New York, NY
- Format: Fireside chat & 1x1 meetings
- Time: 8:00 a.m. ET

3. Morgan Stanley 23rd Annual Global Healthcare Conference
- Date: Wednesday, September 10th, 2025
- Location: New York, NY
- Format: Fireside chat & 1x1 meetings
- Time: 8:30 a.m. ET

Live webcasts of the fireside chats will be available by visiting the “Investors & Media” section of the Arcus Biosciences website at www.arcusbio.com. Replays will be available following the live event.

Analyst ratings and market metrics for Arcus Biosciences highlight a mixed outlook. Bank of America Securities analyst Jason Zemansky reiterated a Hold rating on the company with a $12.00 price target. In contrast, Arcus Biosciences has a Strong Buy analyst consensus rating with an average price target of $28.86, representing a 174.07% upside. The company has a market cap of $1.12 billion and a P/E ratio of -3.32.

Arcus Biosciences focuses on developing differentiated molecules and combination therapies for patients with cancer. The company's pipeline includes domvanalimab, an Fc-silent anti-TIGIT antibody in combination with zimberelimab, an anti-PD-1 antibody, for upper gastrointestinal and non-small cell lung cancer; casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma; and quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer [1].

References:

[1] https://www.biospace.com/press-releases/arcus-biosciences-to-participate-in-three-upcoming-september-2025-investor-conferences